Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could AI help pharmacists give better advice?

NCT ID NCT07649577

Knowledge-focused Sponsor: University of Petra Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether pharmacists using a generative AI tool (ChatGPT) can provide more accurate and complete medication counseling compared to standard practice. The trial involves 136 adults with chronic conditions like diabetes, high blood pressure, or asthma who are picking up prescriptions. The goal is to see if AI assistance improves the correctness of counseling and whether patients are more likely to take their medications as prescribed over 30 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ChatGPT (generative AI) used by pharmacists for medication counseling
What this could lead to
If successful, this could show that AI helps pharmacists provide more accurate and complete medication information, potentially improving patient adherence.
What could go wrong
This is a small, early-stage study in Jordan, so results may not apply broadly. AI may still produce errors or miss important details.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

136 people

The number who actually took part.

Started

Jan 2026

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patient Eligibility Criteria Inclusion Criteria: Adults aged 18 years or older. Presenting with a new prescription or a refill for a chronic medication requiring counseling within one of the following classes: antihypertensives, oral antidiabetics, lipid-lowering agents, anticoagulants, or inhaled maintenance therapies. Willing and able to provide informed consent. Exclusion Criteria: Presence of acute infections. Diagnosis of psychiatric disorders or oncological conditions. Presence of severe acute illness requiring urgent medical referral. Cognitive impairment precluding informed consent. Hearing or communication barriers that prevent interview completion without the presence of a caregiver. Inability to provide a follow-up phone number for the 30-day adherence assessment. Pharmacy and Pharmacist (Cluster) Eligibility Criteria Inclusion Criteria: Pharmacies legally registered in Jordan, providing routine prescription dispensing services, having at least one licensed pharmacist available during recruitment hours, and agreeing to participate for the full trial period. Licensed pharmacists with a minimum of 2 years of clinical experience, working in participating pharmacies, providing direct patient counseling, and consenting to take part in the study. Exclusion Criteria: Pharmacies that are already using structured AI-assisted counseling tools as part of their routine practice. Pharmacists on temporary placement for less than one month. Pharmacists not involved in patient-facing counseling.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma cardiovascular disorder Chronic Disease chronic obstructive pulmonary disease COPD, severe early onset diabetes mellitus Dyslipidemias hyperlipidemia hypertensive disorder inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma Cardiovascular diseases Chronic disease Diabetes mellitus Dyslipidemias Hypertension Pulmonary disease, chronic obstructive

Contacts and locations

Locations

  • Petra University

    Amman, Jordan

More trials for these conditions

Other studies related to the condition(s) this trial covers.